# Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

> **NCT07285239** · PHASE3 · NOT_YET_RECRUITING · sponsor: **PrECOG, LLC.** · enrollment: 500 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Arm A: Belantamab Mafodotin
- **DRUG:** Arm B: Daratumumab Hyaluronidase
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07285239
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2031-11
- **Final completion:** 2034-06
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285239, "Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07285239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*